Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 424
- Registration Number
- NCT00413894
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: epoetin beta [NeoRecormon]
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT00413101
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
Phase 2
Completed
- Conditions
- Emphysema
- Interventions
- Drug: RAR GammaDrug: Placebo
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 491
- Registration Number
- NCT00413205
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 477
- Registration Number
- NCT00412737
A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00412555
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00412334
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Phase 3
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT00412217
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
Phase 3
Completed
- Conditions
- Myasthenia Gravis Generalised
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT00408213
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Platinum-based chemotherapy
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT00404703
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00400361
© Copyright 2025. All Rights Reserved by MedPath